Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 10, 2016

View Archived Issues

Cancer Targeted Technology initiates first-in-human safety and imaging study of CTT-1057

Lee's Pharmaceutical licenses rights to Resolvine ER in Greater China and South East Asia

FDA approves Carnexiv as intravenous short-term replacement therapy for seizures

Aradigm receives funding to develop nanotechnologies targeting bacterial and fungal biofilms

Sun BioPharma advances phase I trial of SBP-101 in pancreatic cancer

Abeona Therapeutics' phase I/II study of ABO-102 allowed to proceed

EnGeneIc and Teva collaborate on EDV-based immunomodulatory therapies for cancer

FDA grants priority review to sBLA for daratumumab in multiple myeloma

Aprea advances high-grade serous ovarian cancer trial of APR-246 into phase II

FDA issues complete response letter for AC-170 NDA

Grunenthal reports preliminary efficacy data of for cebranopadol for cancer-related pain

Ixico participates in AMYPAD project consortium for Alzheimer's disease

Novartis patents FGFR-4 inhibitors

Toray Industries discloses analgesic agents

Intra-Cellular Therapies describes NET and/or SERT ligands

Roche develops BACE1 inhibitors

JW Pharmaceutical reports desfesoterodine derivatives

Novel biomarker of diarrhea in sorafenib-treated patients with mRCC

FDA awards orphan drug designation to ibudilast in ALS

Alexion Pharmaceuticals' ALXN-1007 receives FDA orphan drug designation

Activity of prexasertib investigated in patients with triple-negative breast cancer

DLYE-5953A shows preliminary antitumor efficacy in NSCLC and MBC

Panther Biotechnology requests pre-IND meeting for TRF-DOX

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...